Spelling suggestions: "subject:"aancer treatment."" "subject:"7cancer treatment.""
41 |
AN INTRODUCTION TO A HYPERTHERMIA PATIENT PLANNING AND PATIENT TREATMENT EVALUATION SYSTEM (NUMERICAL, CANCER).Miller, William Harley. January 1985 (has links)
No description available.
|
42 |
Complement-mediated lysis by monoclonal antibodies for human therapyBindon, Carol Ianthe January 1987 (has links)
No description available.
|
43 |
Female breast cancer : The individual experience and social organisation of its diagnosis and treatmentCannon, S. January 1988 (has links)
No description available.
|
44 |
Effects of interstitial laser photoagulation and photodynamic therapy on lung parenchymaFielding, David Ivor Keith January 1997 (has links)
No description available.
|
45 |
Synthetic studies towards pateamineBrookfield, Frederick Arthur January 1999 (has links)
No description available.
|
46 |
The effect of localized hyperthermia on blood flow in tumours and other issuesButts, Geoffrey Ian January 1999 (has links)
No description available.
|
47 |
An evaluation of primary care follow-up of breast cancerGrunfeld, Eva January 1997 (has links)
No description available.
|
48 |
Targeting the PI3K/mTOR and ATK/Chk1 pathways to improve radiation efficacy for cancer therapyFokas, Emmanouil January 2012 (has links)
The purpose of the present thesis was to better understand the effect of targeting key biological mechanisms in order to improve radiotherapy response. Two important and distinct pathways were targeted using novel agents: (1) the phosphoinoside-3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway; (2) the ataxia telangiectasia-mutated-Rad3-related (ATR)/Chkl pathway. The role of the PI3K1mTOR signalling pathway in tumour radiosensitivity and tumour microerivlronment (TME) was examined using three, recently-developed signalling inhibitors obtained from Novartis Pharma: NVP-BEZ235 (dual PI3K1mTOR inhibitor), NVP-BGT226 (dual PI3K1mTOR inhibitor) and NVP-BKM120 (single PI3K inhibitor). The radiosensitising potential of NVP-BEZ235 and NVP-BGT226 was demonstrated in tumour and endothelial cells. Additionally, a thorough research into the effects ofNVP-BKM120 and NVP-BEZ235 on TME showed that oncogenic signalling inhibitors can improve vascular morphology and increase tumour oxygenation and perfusion in tumour xenograft models, resulting in improved radiation response. Furthermore, a highly potent and selective A TR inhibitor, VE-822, that was obtained from Vertex Pharmaceuticals (Europe) Ltd, was tested in pancreatic ductal adenocarcinoma (PDAC) cells and tumour xenograft models. A TR inhibition by VE-822 resulted in sensitisation of tumour cells but not normal cells to radiation and gemcitabine. Similarly, VE-822 strongly enhanced radiation- and chemoradiation-induced tumour growth delay in tumour xenograft models. Importantly, VE-822 did not potentiate radiation-induced gastrointestinal tract epithelial damage. To summarize, the impact of targeting two distinct pathways in combination with radiation and chemoradiation was explored. Inhibition of the PI3K1mTOR and ATRlChkl signalling pathways increases response of tumours to radiotherapy they and might be promising targeting strategies for cancer treatment. Our findings have considerable translational implications and future clinical trials should aim to validate these observations.
|
49 |
Application of anti-LRP/LR specific antibodies on neoplastic cell lines for metastatic cancer treatmentOmar, Aadilah 05 September 2012 (has links)
The 37kDa/67kDa laminin receptor (LRP/LR) is thought to play a major role in the
adhesion to laminin and consequently invasion resulting in the metastasis of tumor
cells. This receptor is reported to be over-expressed in several neoplastic cell lines
and is believed to increase tumor aggressiveness. This research aims at determining
whether the application of anti-LRP/LR specific antibody (IgG1-iS18) on neoplastic
cell lines would result in a decrease in invasion and adhesion. All neoplastic cell lines
had significantly increased cell surface LRP/LR levels compared to NIH/3T3 cells,
with the most notable increase seen in SW480 cells (10.98%). Due to a positive
correlation between the cell surface LRP/LR levels and invasion potential we propose
that an increased LRP/LR level correlates to an increased ability to invade. A
significantly decreased adhesion potential was noted in all neoplastic cell lines except
the non-invasive MCF-7 cell line, upon application of IgG1-iS18, 21% decrease in
HT-1080 cells, 14% in HeLa, 20% in LNCaP, 48% and 74% in A549 and SW480
cells, respectively. Incubation with the anti-LRP/LR antibody IgG1-iS18 resulted in a
significant reduction of the invasive potential of HT-1080 (44%), A549 (33%), HeLa
(69%), SW480 (91%) and LNCaP cells (38%). Furthermore, a high Pearson’s
correlation coefficient between adhesion potential and invasive potential was seen,
confirming that adhesion is indeed a pre-requisite for invasion. The significant
reduction in invasion and adhesion of HT-1080, A549, HeLa, SW480 and LNCaP
cells upon application of the IgG1-iS18 antibody suggests that this macromolecule
might act as a promising therapeutic tool for the treatment of various metastatic
cancer types.
|
50 |
Integrated analysis of ovarian cancer :implications on tissue origin, hormone therapy and immunotherapyHao, Da Peng January 2018 (has links)
University of Macau / Faculty of Health Sciences
|
Page generated in 0.0513 seconds